Form 8-K - Current report:
SEC Accession No. 0001104659-25-091064
Filing Date
2025-09-18
Accepted
2025-09-18 09:15:11
Documents
12
Period of Report
2025-09-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2526076d1_8k.htm   iXBRL 8-K 41202
  Complete submission text file 0001104659-25-091064.txt   211519

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA carm-20250916.xsd EX-101.SCH 3017
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE carm-20250916_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE carm-20250916_pre.xml EX-101.PRE 22360
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2526076d1_8k_htm.xml XML 3698
Mailing Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104
Business Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104 2674916422
Carisma Therapeutics Inc. (Filer) CIK: 0001485003 (see all company filings)

EIN.: 262025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36296 | Film No.: 251321894
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)